Danica Michaličková1, Jan Miroslav Hartinger2, Zuzana Hladinová3, Vladimíra Bednářová3, Barbora Szonowská4, Vladimír Polakovič4, Andreas Matthios2,5, Vladimír Tesař3, Ondřej Slanař2, Elke H J Krekels6. 1. Institute of Pharmacology, First Faculty of Medicine & General University Hospital, Charles University, Prague, Czech Republic. marrtta@gmail.com. 2. Institute of Pharmacology, First Faculty of Medicine & General University Hospital, Charles University, Prague, Czech Republic. 3. Department of Nephrology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic. 4. Internal Department of Strahov, General University Hospital, Prague, Czech Republic. 5. Department of Biophysics and Physical Chemistry, Faculty of Pharmacy, Charles University, Hradec Králové, Czech Republic. 6. Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands.
Abstract
PURPOSE: Data on the anti-Xa efficacy of fondaparinux in dialysis-dependent chronic kidney disease (DD-CKD) patients are scarce. This study characterizes the pharmacokinetics (PK) and pharmacodynamics (PD) of fondaparinux in DD-CKD patients undergoing renal replacement therapy (RRT), to assess dosing strategies. METHODS: A retrospective, observational study was conducted using data on anti-Xa activity (112 samples) from 12 (3 male and 9 female) DD-CKD patients (median (IQR) age 71 years (63-88), weight 73 kg (59-98.5)). Eleven patients underwent high-flux or low-flux hemodialysis (HD) and one patient underwent peritoneal dialysis. Three patients were also treated with therapeutic plasma exchange (TPE). A non-linear mixed effects analysis was performed using NONMEM 7.3.0. RESULTS: The lab-specific slope of the relationship between fondaparinux concentration and anti-Xa levels was 1.18 IU/µg. In a one-compartment model, clearance (CL) and volume of distribution (Vd) were 0.05289 L/h and 5.55 L, respectively. High-flux HD was found to increase the CL of fondaparinux 2.26 times. TPE also considerably increased CL, but the fold-change could not be accurately estimated. Low-flux HD and peritoneal dialysis did not impact PK parameters. CONCLUSIONS: Model-based simulations showed that standard dosing (2.5 mg three times weekly before HD) results in a median anti-Xa activity of 0.55 IU/mL and 0.98 IU/mL, pre- and post-low-flux HD, respectively. In patients undergoing high-flux HD, these values are approximately 27% lower. Additional caution is warranted with TPE, as this treatment can reduce anti-Xa activity even further.
PURPOSE: Data on the anti-Xa efficacy of fondaparinux in dialysis-dependent chronic kidney disease (DD-CKD) patients are scarce. This study characterizes the pharmacokinetics (PK) and pharmacodynamics (PD) of fondaparinux in DD-CKD patients undergoing renal replacement therapy (RRT), to assess dosing strategies. METHODS: A retrospective, observational study was conducted using data on anti-Xa activity (112 samples) from 12 (3 male and 9 female) DD-CKD patients (median (IQR) age 71 years (63-88), weight 73 kg (59-98.5)). Eleven patients underwent high-flux or low-flux hemodialysis (HD) and one patient underwent peritoneal dialysis. Three patients were also treated with therapeutic plasma exchange (TPE). A non-linear mixed effects analysis was performed using NONMEM 7.3.0. RESULTS: The lab-specific slope of the relationship between fondaparinux concentration and anti-Xa levels was 1.18 IU/µg. In a one-compartment model, clearance (CL) and volume of distribution (Vd) were 0.05289 L/h and 5.55 L, respectively. High-flux HD was found to increase the CL of fondaparinux 2.26 times. TPE also considerably increased CL, but the fold-change could not be accurately estimated. Low-flux HD and peritoneal dialysis did not impact PK parameters. CONCLUSIONS: Model-based simulations showed that standard dosing (2.5 mg three times weekly before HD) results in a median anti-Xa activity of 0.55 IU/mL and 0.98 IU/mL, pre- and post-low-flux HD, respectively. In patients undergoing high-flux HD, these values are approximately 27% lower. Additional caution is warranted with TPE, as this treatment can reduce anti-Xa activity even further.
Authors: Ron J Keizer; Michel van Benten; Jos H Beijnen; Jan H M Schellens; Alwin D R Huitema Journal: Comput Methods Programs Biomed Date: 2010-06-02 Impact factor: 5.428
Authors: Robert M Kalicki; Fabienne Aregger; Lorenzo Alberio; Bernhard Lämmle; Felix J Frey; Dominik E Uehlinger Journal: Thromb Haemost Date: 2007-12 Impact factor: 5.249
Authors: François Donat; Jean Pierre Duret; Alix Santoni; Roger Cariou; José Necciari; Harry Magnani; Rik de Greef Journal: Clin Pharmacokinet Date: 2002 Impact factor: 6.447
Authors: Elien Mahieu; Kathleen Claes; Marc Jacquemin; Pieter Evenepoel; Karel Op De Beek; Anne-Marie Bogaert; Dirk Kuypers; Peter Verhamme; Björn Meijers Journal: Artif Organs Date: 2013-03-05 Impact factor: 3.094